This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoang, J. K. Articles by Patz, E. F. Search for Related Content PubMed PubMed Citation Articles by Hoang, J. K. Articles by Patz, E. F., Jr Social Bookmarking                            What's this?

Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non–Small-Cell Lung Carcinoma

Jenny K. Hoang, Luke F. Hoagland, R. Edward Coleman, April D. Coan, James E. Herndon, II, Edward F. Patz, Jr

From the Departments of Radiology and Pharmacology and Cancer Biology, and Cancer Center Biostatistics, Duke University Medical Center, Durham, NC

Corresponding author: Edward F. Patz Jr, MD, Department of Radiology, Duke University Medical Center, Erwin Rd, Durham, NC 27710; e-mail: patz0002{at}mc.duke.edu

Purpose To determine whether the amount of fluorine-18 fluorodeoxyglucose (FDG) uptake in the primary lung cancer on positron emission tomography (PET) imaging at the time of presentation has prognostic significance in patients with advanced-stage non–small-cell lung cancer (NSCLC).

Patients and Methods A retrospective review identified 214 patients with advanced-stage NSCLC (stage IIIA, IIIB, and IV) who underwent FDG PET study at the time of diagnosis. Extensive clinical data, including tumor histologic cell type, pathologic stage at presentation, and treatment, were recorded. The maximum standardized uptake value (SUV_max) in the primary tumor on FDG PET on survival was examined using Cox proportional hazards regression.

Results One hundred fifty-eight (74%) of the 214 patients died and 56 patients were reported alive at 27 months (range, 3 to 140 months) after the diagnosis of NSCLC. Using the median SUV_max of 11.1, the patient population was subdivided. The median survival of the 106 patients with the primary tumor having an SUV_max less than 11.1 was 16 months (95% CI, 12 to 21 months), whereas the median survival of the 108 patients with the primary tumor having an SUV_max 11.1 was 12 months (95% CI, 10 to 15 months). Univariate and multivariate analysis did not provide evidence that survival for patient subgroups defined by the median SUV_max were significantly different (univariate P = .11; multivariate P = .45).

Conclusion FDG uptake of the primary lesions in patients with a new diagnosis of advanced-stage NSCLC does not have a significant relationship with survival.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Kaira, N. Oriuchi, K. Shimizu, H. Tominaga, N. Yanagitani, N. Sunaga, T. Ishizuka, Y. Kanai, M. Mori, and K. Endo 18F-FMT Uptake Seen Within Primary Cancer on PET Helps Predict Outcome of Non-Small Cell Lung Cancer J. Nucl. Med., November 1, 2009; 50(11): 1770 - 1776. [Abstract] [Full Text] [PDF]

				J. J. Erasmus, E. Rohren, and S. G. Swisher Prognosis and Reevaluation of Lung Cancer by Positron Emission Tomography Imaging Proceedings of the ATS, April 15, 2009; 6(2): 171 - 179. [Abstract] [Full Text] [PDF]

				Y. J. Lee, A. Cho, B. C. Cho, M. Yun, S. K. Kim, J. Chang, J. W. Moon, I. K. Park, H. J. Choi, and J.-H. Kim High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2426 - 2432. [Abstract] [Full Text] [PDF]